The primary objective of this clinical research study is to assess the safety and efficacy of
rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C
≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor
surgical procedures).